Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib?onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.

Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib?onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res. 2014 Sep 01; 20(17):4488-98.

View in: PubMed

subject areas

Adolescent
Adult
Aged
Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Disease-Free Survival
ErbB Receptors
Erlotinib Hydrochloride
Female
Gene Expression Regulation, Neoplastic
Humans
In Situ Hybridization, Fluorescence
Male
Middle Aged
Neoplasm Staging
Proto-Oncogene Proteins c-met
Quinazolines
RNA, Messenger

authors with profiles

IGNACIO IVAN WISTUBA